strong achiev guidanc
top bottom line beat guidanc light top-line
report revenu consensu estim
driven strong soliri includ gmg perform bottom line also beat
estim vs consensu driven higher expect soliri revenu
provid revenu guidanc includ
soliris/ultomiri sale metabol franchis revenu note
guidanc includ price headwind fx headwind
headwind convers smaller intern market distributor adjust ep
guidanc consensu adjust adjust ep
accordingli reiter buy rate alxn strong top-line growth
ultomiri approv decemb begun convers strategi
success convert soliri patient ultomiri januari continu
aim rapid convers patient soliri ultomiri target year
convers rate expect approxim linear convers growth rate
would put compani track meet goal alxn abil execut
ambiti convers target could critic protect complement franchis
eros due competit biosimilar end believ
discount ultomiri compar soliri pnh mainten phase
discount ahu mg facilit convers
expand pipelin new indic asset
receiv posit data phase studi ultomiri ahu plan
file regulatori approv us follow eu japan also
initi phase studi ultomiri gmg report data
subcutan formul ultomiri pnh ahu earlier
pipelin announc initi two pivot trial waiha
gmg proof-of-concept studi ultomiri al ppm
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
